Brønden, A1; Hansen, M1; Sonne, D P1; Rohde, U1; Vilsbøll, T1; Knop, F K1
1 Internal Medicine, Gentofte, Herlev and Gentofte Hospital, The Capital Region of Denmark
a phosphate-binding resin with glucose-lowering potential
Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.
Diabetes, Obesity and Metabolism, 2014, Vol 17, Issue 2, p. 116-120